Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

Immune cell - derived microparticles contribute to the resistance of rheumatoid arthritis synovial fibroblasts to death receptor-mediated apoptosis

Authors: Mojca Frank, Meike Dahlhaus, Maria Filkova, Christoph Kolling, Beat A Michel, Diego Kyburz, Blaž Rozman, Renate E Gay, David Pisetsky, Steffen Gay, Astrid Jüngel

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Immune cell-derived microparticles (MPs) are present at increased amounts in synovial fluid of rheumatoid arthritis (RA) patients [1] and can activate disease-relevant signalling pathways in RA synovial fibroblasts (SF) [2, 3]. Increased resistance to apoptosis is one of the main characteristics of aggressive phenotype of RASF [4, 5] and MPs have been shown to mediate both pro- and anti- apoptotic effects in different target cells [6, 7]. The aim of the present study was to investigate the functional role of immune cell-derived MPs in modulating the apoptosis of SF in RA. …
Literature
1.
Berckmans RJ, Nieuwland R, Kraan MC, Schaap MC, Pots D, Smeets TJ, Sturk A, Tak PP: Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther. 2005, 7 (3): R536-544. 10.1186/ar1706.PubMedCentralCrossRefPubMed
2.
Beyer C, Pisetsky DS: The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol. 2010, 6 (1): 21-29. 10.1038/nrrheum.2009.229.CrossRefPubMed
3.
Distler JH, Jüngel A, Huber LC, Seemayer CA, Reich CF, Gay RE, Michel BA, Fontana A, Gay S, Pisetsky DS, Distler O: The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA. 2005, 102 (8): 2892-2897. 10.1073/pnas.0409781102.PubMedCentralCrossRefPubMed
4.
Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K, Seyfert C, van Valen F, Pap T, Meinecke I: Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther. 2009, 11 (1): R16-10.1186/ar2607.PubMedCentralCrossRefPubMed
5.
Korb A, Pavenstädt H, Pap T: Cell death in rheumatoid arthritis. Apoptosis. 2009, 14 (4): 447-454. 10.1007/s10495-009-0317-y.CrossRefPubMed
6.
Distler JH, Akhmetshina A, Dees C, Jüngel A, Stürzl M, Gay S, Pisetsky DS, Schett G, Distler O: Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum. 2011, 63 (7): 2067-2077. 10.1002/art.30361.CrossRefPubMed
7.
Castellana D, Zobairi F, Martinez MC, Panaro MA, Mitolo V, Freyssinet JM, Kunzelmann C: Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res. 2009, 69 (3): 785-793. 10.1158/0008-5472.CAN-08-1946.CrossRefPubMed
Metadata
Title
Immune cell - derived microparticles contribute to the resistance of rheumatoid arthritis synovial fibroblasts to death receptor-mediated apoptosis
Authors
Mojca Frank
Meike Dahlhaus
Maria Filkova
Christoph Kolling
Beat A Michel
Diego Kyburz
Blaž Rozman
Renate E Gay
David Pisetsky
Steffen Gay
Astrid Jüngel
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3616

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Oral presentation

IL-17, synoviolin and rheumatoid arthritis chronicity

Poster presentation

Pathogenic protease expression in murine OA is critically dependent upon mechanical joint loading

Poster presentation

Cartilage-specific deletion of prar-gamma in mice results in early endochondral ossification defects and accelerated aging-dependent development of osteoarthritis

Oral presentation

Assessment of histological alterations in cartilage and extracellular matrix driven by collagen-induced arthritis in Macaca fascicularis

Oral presentation

Innate and adaptive immune responses to dead and dying cells

Oral presentation

Regulation of immune cell responses by semaphorins and their receptors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits